AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30098513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile marital interactions with mood disorder history
Number of subjects: 86
Study 30098513 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LBP
Number of subjects: 86
Study 30098513 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sCD14
Number of subjects: 86
Study 29469430 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional nursing plus solution focused approach
Number of subjects: 53
Study 29469430 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing
Number of subjects: 53
Study 24895288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 48
Study 24895288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23254795 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 208
Study 20593555 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 45
Study 20593555 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP with 900 ppm fluoride
Number of subjects: 45
Study 20593555 — intervention group
Group type: COMPARATOR
Intervention: Saliva (control)
Number of subjects: 45
Study 18514729 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (35 mg once a day)
Number of subjects: 120
Study 18514729 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 120
Study 15793255 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 2343
Study 15793255 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 2343
Study 15793255 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2343
Study 15793255 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 2343
Study 15793255 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (after withdrawal)
Number of subjects: 2343
Study 11922229 — intervention group
Group type: EXPERIMENTAL
Intervention: Inolter
Number of subjects: 60
Study 10417579 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical onion gel extract
Number of subjects: 17
Study 10417579 — intervention group
Group type: COMPARATOR
Intervention: Topical emollient ointment (petrolatum based)
Number of subjects: 17
Study 8824652 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine b.d.
Number of subjects: 11
Study 8824652 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m.
Number of subjects: 11
Study 8824652 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole o.m.
Number of subjects: 11
Study 8824652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1904681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (2 months before hysterectomy)
Number of subjects: 50
Study 1904681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no agonist)
Number of subjects: 50
Study 31455700 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive case detection by CHWs with daily home visits and doorstep services
Number of subjects: 137
Study 31455700 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach to iCCM service delivery with services provided exclusively out of a fixed community health site
Number of subjects: 137
Study 28560470 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 28560470 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 25263215 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Number of subjects: 44
Study 25263215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23369425 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) training
Number of subjects: 30
Study 23369425 — intervention group
Group type: COMPARATOR
Intervention: Concentric (CON) training
Number of subjects: 30
Study 21233468 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS)
Number of subjects: 8
Study 21233468 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (S‐tDCS)
Number of subjects: 8
Study 19584192 — intervention group
Group type: EXPERIMENTAL
Intervention: Add teriparatide (20 microg/d)
Number of subjects: 0
Study 19584192 — intervention group
Group type: COMPARATOR
Intervention: Switch to teriparatide (20 microg/d)
Number of subjects: 0
Study 18181517 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethoxyethylacrylate-coated circuits + Leukocyte filters
Number of subjects: 120
Study 18181517 — intervention group
Group type: COMPARATOR
Intervention: Control: Uncoated circuits
Number of subjects: 120
Study 15019156 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day for one year)
Number of subjects: 0
Study 15019156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11464352 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-diluted 0.25% lidocaine
Number of subjects: 61
Study 11464352 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-diluted 0.25% mepivacaine
Number of subjects: 61
Study 11464352 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-diluted 0.2% lidocaine
Number of subjects: 61
Study 9669136 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Ketoconazole shampoo
Number of subjects: 0
Study 9669136 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Minoxidil therapy
Number of subjects: 0
Study 9669136 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated shampoo
Number of subjects: 0
Study 7520956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil and intravenous folinic acid Days 1-6 after operation
Number of subjects: 26
Study 7520956 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 26
Study 3180905 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin‐propionate‐N‐acetylcysteinate (EPAC)
Number of subjects: 30
Study 3180905 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate (ES)
Number of subjects: 30
Study 4212040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus daily granulocyte transfusion
Number of subjects: 0
Study 4212040 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin alone
Number of subjects: 0
Study 30553440 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (tuck-and-roll strategy)
Number of subjects: 14
Study 30553440 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 14
Study 28001306 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (plasma concentration 1,000‐3,500 ng/mL)
Number of subjects: 0
Study 28001306 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (plasma concentration 100‐200 ng/mL)
Number of subjects: 0
Study 26302453 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time (JiT) instructions with Combat Application Tourniquet (C-A-T)
Number of subjects: 194
Study 26302453 — intervention group
Group type: COMPARATOR
Intervention: No instructions (Control)
Number of subjects: 194
Study 24253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SMUG1 mRNA expression
Number of subjects: 249
Study 24253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SMUG1 protein expression
Number of subjects: 249
Study 24253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SMUG1 protein expression in ER+ cohort receiving adjuvant endocrine therapy
Number of subjects: 249
Study 24253812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SMUG1 protein expression in ER- cohort receiving adjuvant chemotherapy
Number of subjects: 249
Study 21704237 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release tramadol/acetaminophen (tramadol 75 mg/acetaminophen 650 mg)
Number of subjects: 12
Study 21704237 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tramadol/acetaminophen (tramadol 37.5 mg/acetaminophen 325 mg)
Number of subjects: 12
Study 21704237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (ER and IR)
Number of subjects: 12
Study 19565043 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation in adults with a BMI > 25
Number of subjects: 459
Study 19565043 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation in adults
Number of subjects: 459
Study 19565043 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional constipation in low educated women
Number of subjects: 459
Study 16384765 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene gel 1% with narrowband UVB phototherapy
Number of subjects: 9
Study 16384765 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel with narrowband UVB phototherapy
Number of subjects: 9
Study 12771113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate)
Number of subjects: 4532
Study 12771113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4532
Study 12771113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 4532
Study 10852275 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg i.v. pulse of methylprednisolone followed by 0.7 mg/kg/day oral prednisone (Group 1)
Number of subjects: 164
Study 10852275 — intervention group
Group type: COMPARATOR
Intervention: 0.7 mg/kg/day prednisone without an i.v. pulse (Group 2, controls)
Number of subjects: 164
Study 10852275 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg i.v. pulse of methylprednisolone followed by 0.5 mg/kg/day prednisone (Group 3)
Number of subjects: 164
Study 10852275 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid resistance
Number of subjects: 164
Study 10852275 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid related side effects
Number of subjects: 164
Study 9089425 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF) 25 mg
Number of subjects: 12
Study 9089425 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF) 50 mg
Number of subjects: 12
Study 9089425 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF) 100 mg
Number of subjects: 12
Study 9089425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9089425 — intervention group
Group type: EXPERIMENTAL
Intervention: SDZ HTF 919 (HTF)
Number of subjects: 12
Study 8385176 — intervention group
Group type: EXPERIMENTAL
Intervention: Human BNP (2 pmol/kg per min)
Number of subjects: 6
Study 8385176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 6
Study 3643648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral course of pivampicillin/pivmecillinam (PAPM)
Number of subjects: 261
Study 3643648 — intervention group
Group type: COMPARATOR
Intervention: Parenteral cefotaxime (CFT)
Number of subjects: 261
Study 31019486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver without intervals between positions (group A)
Number of subjects: 40
Study 31019486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver with 3 min intervals between positions (group B)
Number of subjects: 40
Study 31019486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver with intervals (group B)
Number of subjects: 40
Study 28693484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention involving 12 months of £20 vouchers for physical activities, peer mentor scheme, advocacy meetings
Number of subjects: 7
Study 28693484 — intervention group
Group type: COMPARATOR
Intervention: Control schools continuing usual practice
Number of subjects: 7
Study 25837829 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir plus paritaprevir plus ritonavir with ribavirin
Number of subjects: 135
Study 25837829 — intervention group
Group type: COMPARATOR
Intervention: ombitasvir plus paritaprevir plus ritonavir without ribavirin
Number of subjects: 135
Study 25837829 — intervention group
Group type: EXPERIMENTAL
Intervention: ribavirin-containing regimen
Number of subjects: 135
Study 24169120 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaVir (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13; 0.8 mg at weeks 0, 1, 6, 7, 12, and 13)
Number of subjects: 6
Study 24169120 — intervention group
Group type: EXPERIMENTAL
Intervention: DermaVir (intermediate-dose)
Number of subjects: 6
Study 24169120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 22023876 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone tablets
Number of subjects: 0
Study 22023876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19916848 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (58.3 mg/day)
Number of subjects: 16
Study 19916848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17030114 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium skim milk with added phylloquinone (80 microg/d)
Number of subjects: 82
Study 17030114 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium skim milk without added phylloquinone (1000 mg/d of extra calcium)
Number of subjects: 82
Study 17030114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 82
Study 15098126 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-Body Mass (TBM) protocol
Number of subjects: 0
Study 15098126 — intervention group
Group type: COMPARATOR
Intervention: Fat-Free Mass (FFM) protocol
Number of subjects: 0
Study 15098126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TBM and FFM protocols
Number of subjects: 0
Study 11345281 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 209
Study 11345281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 9408414 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy (ML)
Number of subjects: 62
Study 9408414 — intervention group
Group type: COMPARATOR
Intervention: Conventional Approach (CA)
Number of subjects: 62
Study 9408414 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy (ML) and Conventional Approach (CA)
Number of subjects: 62
Study 8431122 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 0
Study 8431122 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin plus warfarin therapy
Number of subjects: 0
Study 8431122 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0
Study 3315582 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC 30U
Number of subjects: 36
Study 3315582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29476713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS)
Number of subjects: 28
Study 29476713 — intervention group
Group type: COMPARATOR
Intervention: Conventional core stabilization
Number of subjects: 28
Study 27323348 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC arm (four cycles of TC, IDS, and four cycles of TC)
Number of subjects: 301
Study 27323348 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (PDS followed by eight cycles of TC)
Number of subjects: 301
Study 25591516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin for 10 days
Number of subjects: 185
Study 25591516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin for 20 days
Number of subjects: 185
Study 25591516 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (Control)
Number of subjects: 185
Study 22459697 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of assistance training followed by 4 weeks of resistance training
Number of subjects: 10
Study 22459697 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of resistance training followed by 4 weeks of assistance training
Number of subjects: 10
Study 20810214 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 60 mg
Number of subjects: 639
Study 20810214 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 639
Study 18704485 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused parathyroidectomy (FP)
Number of subjects: 48
Study 18704485 — intervention group
Group type: COMPARATOR
Intervention: Bilateral neck exploration (BNE)
Number of subjects: 48
Study 15969313 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in RCTs by geriatricians
Number of subjects: 0
Study 15969313 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of necessity for RCTs in very elderly subjects
Number of subjects: 0
Study 15969313 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact regarding participation in RCTs
Number of subjects: 0
Study 15969313 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulties in developing RCTs
Number of subjects: 0
Study 15969313 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles in RCT development
Number of subjects: 0
Study 11572288 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V
Number of subjects: 60
Study 11572288 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 60
Study 11572288 — intervention group
Group type: COMPARATOR
Intervention: Prime & Bond NT (Control)
Number of subjects: 60
Study 9773802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (24 mg) plus dexamethasone (12 mg)
Number of subjects: 530
Study 9773802 — intervention group
Group type: COMPARATOR
Intervention: i.v. ondansetron (8 mg) plus dexamethasone (20 mg)
Number of subjects: 530
Study 7824325 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous dose of vancomycin over 90 min upon anesthesia (Group 1)
Number of subjects: 20
Study 7824325 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous dose of vancomycin followed by a second 7.5 mg/kg intravenous dose over 30 min (Group 2)
Number of subjects: 20
Study 2975552 — intervention group
Group type: EXPERIMENTAL
Intervention: Health counselling with home visit by a health visitor
Number of subjects: 60
Study 2975552 — intervention group
Group type: COMPARATOR
Intervention: Routine advice on health hazards of smoking
Number of subjects: 60
Study 31818522 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in shared decision-making
Number of subjects: 311
Study 29952807 — intervention group
Group type: EXPERIMENTAL
Intervention: MINT protocol (32 × 5-sec intermittent grips at maximal intensity with 5-sec rest between sets)
Number of subjects: 20
Study 29952807 — intervention group
Group type: EXPERIMENTAL
Intervention: ZONA protocol (4 × 2-min sustained grips at 30% moderate intensity with 1-min rest between sets)
Number of subjects: 20
Study 29952807 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 20
Study 27682331 — intervention group
Group type: EXPERIMENTAL
Intervention: PSALTI intervention (physiotherapy and speech and language therapy) consisting of education, laryngeal hygiene and hydration, cough suppression techniques, breathing exercises and psychoeducational counselling.
Number of subjects: 75
Study 27682331 — intervention group
Group type: EXPERIMENTAL
Intervention: PSALTI intervention (physiotherapy and speech and language therapy).
Number of subjects: 75
Study 27682331 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (healthy lifestyle advice).
Number of subjects: 75
Study 24069469 — intervention group
Group type: EXPERIMENTAL
Intervention: Health hygiene education intervention including an initial one hour in-class activity and 30-minute refresher activities every two weeks for four months.
Number of subjects: 1089
Study 24069469 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg) treatment followed by health hygiene education intervention.
Number of subjects: 1089
Study 24069469 — intervention group
Group type: COMPARATOR
Intervention: Control group with no health hygiene education intervention after deworming.
Number of subjects: 1089
Study 19755572 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg single dose)
Number of subjects: 33
Study 19755572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16443788 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at rest
Number of subjects: 43
Study 16443788 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion during adenosine-induced hyperemia
Number of subjects: 43
Study 16443788 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 43
Study 14735177 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel plus cisplatin (PC) - Paclitaxel 66 mg/m² i.v. on days 1, 8, and 15; Cisplatin 60 mg/m² i.v. on day 15.
Number of subjects: 140
Study 14735177 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VC) - Vinorelbine 23 mg/m² i.v. on days 1, 8, and 15; Cisplatin 60 mg/m² i.v. on day 15.
Number of subjects: 140
Study 11816531 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of prostaglandin E1 (misoprostol) intravaginal after IUI
Number of subjects: 59
Study 11816531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no misoprostol)
Number of subjects: 59
Study 9441769 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral intake (clear liquid diet on postoperative day 1, regular diet after tolerating 500 cc)
Number of subjects: 96
Study 9441769 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietary advancement (oral intake initiated after bowel function is documented)
Number of subjects: 96
Study 9441769 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral intake
Number of subjects: 96
Study 9441769 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietary advancement
Number of subjects: 96
Study 7898991 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with native phytic acid
Number of subjects: 0
Study 7898991 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with zero phytic acid
Number of subjects: 0
Study 7898991 — intervention group
Group type: EXPERIMENTAL
Intervention: Native phytate-containing formula with increased ascorbic acid (Fe:ascorbic acid molar ratio from 1:2.1 to 1:4.2)
Number of subjects: 0
Study 3281603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at an initial dosage of 5 mg/kg daily
Number of subjects: 52